BMRN FY 2024 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.9B+18.0% YoY

Gross Profit

$2.3B79.7% margin

Operating Income

$484M17.0% margin

Net Income

$427M15.0% margin

EPS (Diluted)

$2.21

Cash Flow

Operating Cash Flow

$573M

Free Cash Flow

$475M

Stock-Based Comp.

$202M

Balance Sheet

Total Assets

$7.0B

Total Liabilities

$1.3B

Stockholders' Equity

$5.7B

Cash & Equivalents

$943M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.9B	$2.4B	+18.0%
Gross Profit	$2.3B	$1.9B	+20.5%
Operating Income	$484M	$186M	+160.6%
Net Income	$427M	$168M	+154.6%